---
document_datetime: 2023-09-21 20:16:12
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/incresync-epar-all-authorised-presentations_en.pdf
document_name: incresync-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 2.9583145
conversion_datetime: 2025-12-27 16:59:24.470734
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | Invented name   | Strength        | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-----------------|-----------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/13/842/001  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 10 tablets  |
| EU/1/13/842/002  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 14 tablets  |
| EU/1/13/842/003  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 28 tablets  |
| EU/1/13/842/004  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 30 tablets  |
| EU/1/13/842/005  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 56 tablets  |
| EU/1/13/842/006  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 60 tablets  |
| EU/1/13/842/007  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 90 tablets  |
| EU/1/13/842/008  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 98 tablets  |
| EU/1/13/842/009  | Incresync       | 12.5 mg / 30 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 100 tablets |
| EU/1/13/842/019  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 10 tablets  |
| EU/1/13/842/020  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 14 tablets  |
| EU/1/13/842/021  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 28 tablets  |
| EU/1/13/842/022  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 30 tablets  |
| EU/1/13/842/023  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 56 tablets  |
| EU/1/13/842/024  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 60 tablets  |
| EU/1/13/842/025  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 90 tablets  |
| EU/1/13/842/026  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 98 tablets  |
| EU/1/13/842/027  | Incresync       | 25 mg / 30 mg   | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 100 tablets |

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | Invented name   | Strength      | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-----------------|---------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/13/842/028  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 10 tablets  |
| EU/1/13/842/029  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 14 tablets  |
| EU/1/13/842/030  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 28 tablets  |
| EU/1/13/842/031  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 30 tablets  |
| EU/1/13/842/032  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 56 tablets  |
| EU/1/13/842/033  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 60 tablets  |
| EU/1/13/842/034  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 90 tablets  |
| EU/1/13/842/035  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 98 tablets  |
| EU/1/13/842/036  | Incresync       | 25 mg / 45 mg | Film-coated tablet    | Oral use                  | blister (NYL/alu/PVC) | 100 tablets |